Harvard Bioscience (HBIO)
(Delayed Data from NSDQ)
$3.62 USD
+0.06 (1.69%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.63 +0.01 (0.28%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Income Statements
Fiscal Year end for Harvard Bioscience, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 112 | 113 | 119 | 102 | 116 |
Cost Of Goods | 46 | 53 | 51 | 44 | 52 |
Gross Profit | 66 | 61 | 68 | 58 | 64 |
Selling & Adminstrative & Depr. & Amort Expenses | 64 | 68 | 66 | 58 | 64 |
Income After Depreciation & Amortization | 2 | -7 | 2 | 0 | 0 |
Non-Operating Income | -1 | 0 | -1 | -3 | 0 |
Interest Expense | 4 | 3 | 2 | 5 | 5 |
Pretax Income | -3 | -9 | 0 | -7 | -6 |
Income Taxes | 1 | 0 | 0 | 1 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -3 | -10 | 0 | -8 | -5 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -3 | -10 | 0 | -8 | -5 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 9 | 1 | 10 | 9 | 8 |
Depreciation & Amortization (Cash Flow) | 7 | 8 | 8 | 9 | 8 |
Income After Depreciation & Amortization | 2 | -7 | 2 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 42.42 | 41.41 | 40.34 | 38.64 | 37.81 |
Diluted EPS Before Non-Recurring Items | 0.06 | 0.03 | 0.18 | 0.07 | 0.12 |
Diluted Net EPS (GAAP) | -0.08 | -0.23 | -0.01 | -0.20 | -0.12 |
Fiscal Year end for Harvard Bioscience, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 28.15 | 25.36 | 28.76 | 29.98 |
Cost Of Goods | NA | 11.83 | 10.64 | 12.09 | 11.63 |
Gross Profit | NA | 16.33 | 14.73 | 16.67 | 18.35 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 16.05 | 15.66 | 15.88 | 16.60 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.28 | -0.93 | 0.79 | 1.75 |
Non-Operating Income | NA | -0.59 | 1.25 | -1.95 | 0.43 |
Interest Expense | NA | 0.79 | 0.88 | 0.94 | 0.97 |
Pretax Income | NA | -1.10 | -0.56 | -2.10 | 1.21 |
Income Taxes | NA | 0.72 | 0.68 | -1.12 | 0.59 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -1.82 | -1.24 | -0.98 | 0.62 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -1.82 | -1.24 | -0.98 | 0.62 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 42.71 | 42.69 | 42.35 | 42.78 |
Diluted EPS Before Non-Recurring Items | NA | 0.01 | -0.02 | 0.03 | 0.04 |
Diluted Net EPS (GAAP) | NA | -0.04 | -0.03 | -0.02 | 0.01 |